• Disease
  • Retroperitoneal
  • Retroperitoneal Sarcoma
  • Alessandro Gronchi

    Prominent publications by Alessandro Gronchi

    KOL Index score: 19396

    BACKGROUND: Previous trials from our group suggested an overall survival benefit with five cycles of adjuvant full-dose epirubicin plus ifosfamide in localised high-risk soft-tissue sarcoma of the extremities or trunk wall, and no difference in overall survival benefit between three cycles versus five cycles of the same neoadjuvant regimen. We aimed to show the superiority of the neoadjuvant administration of histotype-tailored regimen to standard chemotherapy.

    METHODS: For this ...

    Also Ranks for: Tissue Sarcoma |  risk soft |  neoadjuvant chemotherapy |  survival benefit |  trunk wall
    KOL Index score: 18731

    Importance: Patients with soft tissue sarcoma are at risk for local recurrence and distant metastases despite optimal local treatment. Preoperative anthracycline plus ifosfamide chemotherapy improves outcome in common histological subtypes.

    Objective: To analyze whether the previously reported improvement in local progression-free survival by adding regional hyperthermia to neoadjuvant chemotherapy translates into improved survival.

    Design, Setting, and Participants: Open-label, phase 3 ...

    Also Ranks for: Neoadjuvant Chemotherapy |  regional hyperthermia |  soft tissue |  95 patients |  eortc 62961
    KOL Index score: 18068

    PURPOSE: To compare radiologic response as defined according to both Response Evaluation Criteria in Solid Tumors (RECIST) and the new Choi criteria recently proposed for gastrointestinal stromal tumors with pathologic response in high-grade soft-tissue sarcomas (STSs) treated with preoperative chemotherapy and radiation therapy.

    MATERIALS AND METHODS: The institutional ethical committee approved the trial in which patients were enrolled. Signed informed consent was obtained. ...

    Also Ranks for: Choi Criteria |  pathologic response |  radiation therapy |  tumor size |  tissue sarcomas
    KOL Index score: 17778

    BACKGROUND: Pathological complete response to preoperative treatment in adults with soft-tissue sarcoma can be achieved in only a few patients receiving radiotherapy. This phase 2-3 trial evaluated the safety and efficacy of the hafnium oxide (HfO2) nanoparticle NBTXR3 activated by radiotherapy versus radiotherapy alone as a pre-operative treatment in patients with locally advanced soft-tissue sarcoma.

    METHODS: Act.In.Sarc is a phase 2-3 randomised, multicentre, international trial. ...

    Also Ranks for: Nbtxr3 Radiotherapy |  tissue sarcoma |  preoperative treatment |  hafnium oxide |  primary endpoint
    KOL Index score: 17019

    We investigated the activation of platelet-derived growth factor (PDGF) receptor A (PDGFRA), PDGF receptor B (PDGFRB), epidermal growth factor receptor (EGFR), and their downstream pathways in malignant peripheral nerve sheath tumors (MPNSTs). PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogenetically, and mutationally analyzed along with the detection of their cognate ligands in 16 neurofibromatosis type 1 (NF1)-related and 11 sporadic MPNSTs. The activation of ...

    Also Ranks for: Nerve Sheath |  oncogene proteins |  situ hybridization |  downstream signaling |  plateletderived growth factor
    KOL Index score: 15616

    BACKGROUND: Unlike for extremity sarcomas, the efficacy of radiotherapy for retroperitoneal sarcoma is not established. The aim of this study was to evaluate the impact of preoperative radiotherapy plus surgery versus surgery alone on abdominal recurrence-free survival.

    METHODS: EORTC-62092 is an open-label, randomised, phase 3 study done in 31 research institutions, hospitals, and cancer centres in 13 countries in Europe and North America. Adults (aged ≥18 years) with histologically ...

    Also Ranks for: Preoperative Radiotherapy |  retroperitoneal sarcoma |  surgery patients |  recurrence free |  neoadjuvant therapy
    KOL Index score: 15132

    BACKGROUND: The current American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) staging system does not have sufficient details to encompass the variety of soft-tissue sarcomas, and available prognostic methods need refinement. We aimed to develop and externally validate two prediction nomograms for overall survival and distant metastases in patients with soft-tissue sarcoma in their extremities.

    METHODS: Consecutive patients who had had an operation at the ...

    Also Ranks for: Distant Metastases |  external validation |  nomograms survival |  tissue sarcoma |  retrospective analysis
    KOL Index score: 12528

    PURPOSE: In 2004, we started an intergroup randomized trial of adjuvant imatinib versus no further therapy after R0-R1 surgery patients with localized, high- or intermediate-risk GI stromal tumor (GIST).

    PATIENTS AND METHODS: Patients were randomly assigned to 2 years of imatinib 400 mg daily or no further therapy after surgery. The primary end point was overall survival; relapse-free survival (RFS), relapse-free interval, and toxicity were secondary end points. In 2009, given the ...

    Also Ranks for: French Sarcoma |  adjuvant imatinib |  stromal tumors |  tyrosine kinase |  advanced gist
    KOL Index score: 12477

    BACKGROUND: The use of potential surrogate end points for overall survival, such as disease-free survival (DFS) or time-to-treatment failure (TTF) is increasingly common in randomized controlled trials (RCTs) in cancer. However, the definition of time-to-event (TTE) end points is rarely precise and lacks uniformity across trials. End point definition can impact trial results by affecting estimation of treatment effect and statistical power. The DATECAN initiative (Definition for the ...

    Also Ranks for: Gastrointestinal Stromal Tumors |  definition event |  datecan initiative |  tte points |  cancer trials
    KOL Index score: 12387

    Inflammatory mediators present in the tumor milieu may promote cancer progression and are considered promising targets of novel biological therapies. We previously reported that the marine antitumor agent trabectedin, approved in Europe in 2007 for soft tissue sarcomas and in 2009 for ovarian cancer, was able to downmodulate the production of selected cytokines/chemokines in immune cells. Patients with myxoid liposarcoma (MLS), a subtype characterized by the expression of the oncogenic ...

    Also Ranks for: Liposarcoma Cells |  inflammatory mediators |  cell tumor |  trabectedin production |  antigens differentiation
    KOL Index score: 12324

    BACKGROUND: The objective of this study was to compare the prognostic relevance of Response Evaluation Criteria in Solid Tumors (RECIST) versus Choi criteria for the assessment of response in patients with high-risk soft tissue sarcoma of the extremities or trunk wall who received preoperative chemotherapy with or without radiotherapy in a phase 3 trial.

    METHODS: Patients received 3 cycles of preoperative epirubicin + ifosfamide with or without radiotherapy. The diagnostic concordance ...

    Also Ranks for: Choi Criteria |  soft tissue |  response assessment |  preoperative chemotherapy |  patients recist
    KOL Index score: 11762

    BACKGROUND: Previous studies have suggested that trabectedin (ecteinascidin-743) could have antitumour activity in soft-tissue sarcoma. We aimed to study the usefulness of trabectedin in the treatment of patients with myxoid liposarcomas, a subtype of liposarcoma that is associated with specific chromosomal translocations t(12;16)(q13;p11) or t(12;22)(q13;q12) that result in the formation of DDIT3-FUS or DDIT3-EWSR1 fusion proteins.

    METHODS: 51 patients with advanced pretreated myxoid ...

    Also Ranks for: Patients Trabectedin |  antitumour activity |  myxoid liposarcoma |  progressionfree survival |  advanced pretreated
    KOL Index score: 11440

    BACKGROUND & AIMS: Imatinib, a tyrosine kinase inhibitor of BCR-ABL, KIT, and platelet-derived growth factor receptor, is used in patients with chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). Primary and acquired resistance to the drug can occur in both diseases. Molecular mechanisms have been reported in CML and GIST for primary resistance, whereas extensive studies on the mechanisms responsible for secondary resistance have been almost exclusively ...

    Also Ranks for: Acquired Resistance |  mutation kit |  atp pocket |  gastrointestinal stromal |  imatinib therapy
    KOL Index score: 11321

    BACKGROUND: Retroperitoneal sarcomas (RPS) are rare tumors composed of several well defined histologic subtypes. The aim of this study was to analyze patterns of recurrence and treatment variations in a large population of patients, treated at reference centers.

    METHODS: All consecutive patients with primary RPS treated at 6 European and 2 North American institutions between January 2002 and December 2011 were included. Five, 8, and 10-year overall survival (OS) and crude cumulative ...

    Also Ranks for: Histologic Subtype |  patterns recurrence |  cci dm |  retroperitoneal sarcoma |  primary rps


    Alessandro Gronchi: Influence Statistics

    Sample of concepts for which Alessandro Gronchi is among the top experts in the world.
    Concept World rank
    eortcstbsg #1
    role oligometastatic disease #1
    active observation review #1
    hgrade assessment #1
    dfs s1c #1
    rsts ests #1
    modified grading cthgrade #1
    stss hyperthermia #1
    rsts surgery #1
    preoperative ebrt studies #1
    dm 5 years #1
    variance chemotherapy prrc #1
    survival crude #1
    mvr ghs qol #1
    patients perioperative treatments #1
    worse wd #1
    ipd t41a #1
    grade 3 ddlps #1
    extremities trunk wall #1
    retroperitoneal soft #1
    myxoid chondrosarcoma emc #1
    health workers clinicians #1
    abdominal sporadic #1
    fibromatosis rare #1
    major vascular resections #1
    radiotherapy retroperitoneal sarcomas #1
    case sacral involvement #1
    backgroundretroperitoneal #1
    referral centers #1
    extremity sarcoma ebrt #1
    patients primary rps #1
    involving inferior #1
    g3 ddlps #1
    fpcrrms #1
    art current emc #1
    studies lrsm #1
    treatments tmilp treatments #1
    extra abdominal #1
    dmrisks flexible parametric #1
    sarcoma referral centers #1
    phase italian society #1
    treatment retroperitoneal #1
    tissue oncology #1
    ddlps wdlps #1
    venous homograft replacement #1
    primary retroperitoneal sarcoma #1
    treatment tgct patients #1
    patients advanced chordoma #1
    tumour grade biopsy #1
    approach single patient #1

    Key People For Retroperitoneal Sarcoma

    Top KOLs in the world
    Murray, F Brennan
    gastric cancer soft tissue pancreatic adenocarcinoma
    Sylvie Bonvalot
    soft tissue retroperitoneal sarcoma radiation therapy
    Alessandro Gronchi
    retroperitoneal sarcoma soft tissue neoadjuvant chemotherapy
    Raphael E Pollock
    soft tissue sarcoma surgical resection radiation therapy
    Marco Fiore
    retroperitoneal sarcoma soft tissue single institution
    Paolo Giovanni Casali
    soft tissue rare cancers italian sarcoma

    Alessandro Gronchi:Expert Impact

    Concepts for whichAlessandro Gronchihas direct influence:Retroperitoneal sarcoma,  Soft tissue,  Tissue sarcoma,  Italian sarcoma,  Soft tissue sarcoma,  Neoadjuvant chemotherapy,  Advanced chordoma,  Trunk wall.

    Alessandro Gronchi:KOL impact

    Concepts related to the work of other authors for whichfor which Alessandro Gronchi has influence:Soft tissue,  Gastrointestinal stromal tumors,  Synovial sarcoma,  Surgical resection,  Radiation therapy,  Tumor size,  Imatinib mesylate.



    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

    Departmento of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: alessandro.gronchi@istitutotumori.mi.it. | Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133, Milan,